Inflammatory Bowel Diseases
The four members of the scientific staff that perform basic, translational and clinical research in the field of Inflammatory Bowel Diseases (IBD) are Dr. Andrea van der Meulen, Dr. Jeroen Maljaars, Prof. dr. Hein Verspaget and Prof. Daan Hommes. Our research is focused on several aspects of IBD, with special attention for extra intestinal manifestations of both Crohn’s disease and Ulcerative colitis, E-health and value-based medicine.
Our current projects:
PhD student: drs. Marieke Barnhoorn, MD
PI: prof dr. ir. H. Verspaget and dr. AE van der Meulen – de Jong
• Fecal Microbiota Transplantation. A randomised controlled trial comparing FECal Microbiota Transplantation after BUDesonide or placebo induction in patients with ulcerative colitis: the FECBUD trial
PhD student: drs. Emilie van Lingen, MD
PI: dr. Josbert keller (gastroenterologist MCH, the Hague), prof. dr E. Kuijper, microbiologist, dr. AE van der Meulen – de Jong
PhD student: drs. Vera Ascher, MD
PI: dr. PWJ Maljaars
Post DOC: dr. Ilse Molendijk
PI: dr. PWJ Maljaars
• Implementation of quality improvements within the IBD care
PhD student: drs. Niene Peek, gastroenterologist
PI: dr. A.E. van der Meulen-de Jong and dr. L. Van Bodegom-Vos
• High-Dimensional Single-Cell Analysis By Mass Cytometry (CyTOF) Of The Mucosal Intestinal Immune System In Health And Disease
Goal: To unravel the role of immune subsets in intestinal
pathology using a system-wide analysis approach by combining mass cytometry with computational tools
Collaboration with the department of Immunohematology and Bloodtransfusion
PhD student: Vincent van Unen
PI: Prof dr Frits Koning
Sub-investigator: dr AE van der Meulen – de Jong
Member of the TIMID consortium
Goal: Development and validation of a telemedicine tool to enable continuous monitoring of PROMs and PREMs of all inflammatory bowel disease patients.
Collaboration with Maastricht University Medical Center, and member of Stichting MijnIBDcoach
PI LUMC: dr AE van der Meulen - de Jong
Development and validation of a telemedicine tool to enable continuous monitoring of PROMs and PREMs of all inflammatory bowel disease patients.
Background and motivation
Our pragmatic, randomised trial (n=909) compared the telemedicine tool myIBDcoach with standard outpatient care for patients with inflammatory bowel disease, regardless of disease course or treatment. We found that use of myIBDcoach resulted in a reduction in outpatient visits, telephone consultations, and hospitalisations, and increased adherence to medication. In addition, it was safe and patient-reported quality of healthcare remained consistently high. Link
As active member of the ICC (Initiative Crohn and Colitis) we perform many multicenter studies. Link
Clinical research into new therapies
On the one hand, we conduct our own research into new treatment methods, and on the other we take part in so-called 'clinical trials' (medicine research). In this way we want to operate at the forefront of the development and application of new treatments. In this way, we can also offer patients therapies that are not yet covered by regular care. These studies are organized by the Trial Office of our department, under direct supervision of dr AE van der Meulen – de Jong and dr. PWJ Maljaars.